California Institute for Biomedical Research
California Institute for Biomedical Research is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at California Institute for Biomedical Research.
California Institute for Biomedical Research is a company.
Key people at California Institute for Biomedical Research.
The California Institute for Biomedical Research (Calibr), now known as Calibr-Skaggs Institute for Innovative Medicines, is an independent nonprofit translational research institute founded in 2012 to accelerate the development of new medicines addressing unmet medical needs.[1][2][3] It operates as the drug discovery and development division of Scripps Research, leveraging a self-sustaining "evergreen" model where revenues from commercial partnerships are reinvested into preclinical and clinical research across diseases like cancer, autoimmunity, infectious diseases, and neurodegeneration.[1][3][4] Calibr bridges basic research to clinic-ready therapeutics, including small molecules, peptides, biotherapeutics, and cell therapies, through collaborations with global researchers and industry partners, fostering innovation in a 50,000-square-foot La Jolla facility housing over 130 scientists.[1][3]
Calibr was established in 2012 by Dr. Peter G. Schultz, a renowned chemist and Institute Director, as an independent nonprofit to translate academic discoveries into viable drugs more efficiently than traditional models.[1][2][4] Schultz, who later became CEO of Scripps Research in 2015, built on prior collaborations, leading to a strategic affiliation in October 2016 where Calibr integrated as Scripps' drug discovery arm.[3][4] This evolution shifted Calibr from standalone operations to a division within the larger Scripps ecosystem, enhancing resources while maintaining its focus on bold, high-impact projects; early milestones included antibody platforms for chronic diseases and cancer immunotherapies.[4]
Calibr rides the wave of translational biomedicine, where AI-driven discovery and precision therapies demand faster bridges from lab to clinic amid rising chronic disease burdens and post-pandemic focus on neglected infections.[3] Its timing aligns with biotech's shift toward nonprofit hybrids, countering Big Pharma's risk aversion by de-risking novel mechanisms—Scripps' 1,100+ patents and 11 FDA-approved drugs underscore this ecosystem influence.[4] Market forces like aging populations and antimicrobial resistance favor Calibr's agile model, which has spun insights into 50+ companies via Scripps, amplifying startup momentum in San Diego's biotech hub.[1][4]
Calibr-Skaggs is poised to expand its pipeline through deeper AI integration and global partnerships, targeting Phase II/III trials in oncology and rare diseases while scaling its evergreen model for sustainability.[3][5] Trends like cell/gene therapies and multi-omics will shape its trajectory, potentially yielding more spinouts amid biotech funding rebounds. Its influence may evolve by setting a blueprint for nonprofit drug engines, reinforcing Scripps' leadership and delivering therapies that outpace for-profit timelines—ultimately proving nonprofits can sustain biomedical acceleration.[1][3]
Key people at California Institute for Biomedical Research.
